Helixgate

Helixgate

Uncategorized

STAT+: FDA rejects an industry proposal to deregulate some AI devices

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Everyone told us the Trump administration was going to deregulate medical AI and let developers do whatever they want. And yet, there are some ideas that go too far, it seems.

Continue to STAT+ to read the full story…

Read More

Published

on

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Everyone told us the Trump administration was going to deregulate medical AI and let developers do whatever they want. And yet, there are some ideas that go too far, it seems.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial

Published

on

Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the US.

The open-label Phase 2/3 uveal melanoma trial tested the …

Continue Reading

Uncategorized

Seaport, Hemab set sail for Nasdaq

Published

on

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.

Continue Reading

Uncategorized

Rethinking dermatology trial design for late-stage success

A smarter approach to dermatology trials—built for durability and real-world impact.

Read More

Published

on

A smarter approach to dermatology trials—built for durability and real-world impact.

Read More

Continue Reading
Advertisement

Trending